Driven by innovation and purposeful science
Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology.
SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer.
At SDP Oncology, we are relentlessly exploring novel and unique approaches to address unmet needs in oncology research and development. Through scientific persistence and a commitment to discovery, we are focused on advancing a diverse and purposeful pipeline.
Learn more about our leadership.
SDP Oncology is committed to developing a diverse and purposeful pipeline of novel targets. Augmenting this effort, SDP Oncology’s Global Oncology External Innovation Hub was established to help spark meaningful research in drug discovery for oncology.